Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 22:13:899000.
doi: 10.3389/fendo.2022.899000. eCollection 2022.

An Individualized Recommendation for Controlled Ovary Stimulation Protocol in Women Who Received the GnRH Agonist Long-Acting Protocol or the GnRH Antagonist Protocol: A Retrospective Cohort Study

Ming-Xing Chen  1   2 , Xiang-Qian Meng  3 , Zhao-Hui Zhong  1   4 , Xiao-Jun Tang  4 , Tian Li  5 , Qian Feng  6 , Enoch Appiah Adu-Gyamfi  2 , Yan Jia  7 , Xing-Yu Lv  3 , Li-Hong Geng  7 , Lin Zhu  8 , Wei He  8 , Qi Wan  3 , Yu-Bin Ding  1   2
Affiliations

An Individualized Recommendation for Controlled Ovary Stimulation Protocol in Women Who Received the GnRH Agonist Long-Acting Protocol or the GnRH Antagonist Protocol: A Retrospective Cohort Study

Ming-Xing Chen et al. Front Endocrinol (Lausanne). .

Abstract

Background: The GnRH agonist long-acting protocol and GnRH antagonist protocol are widely used in ovarian stimulation. Which protocol eliciting higher live birth rate for IVF/ICSI patients with different ages, different ovarian reserves and different body mass index (BMI) has not been studied. However, among these protocols, the one that elicits higher live birth in IVF/ICSI patients with different ages, ovarian reserves and body mass indexes (BMI) has not been identified.

Methods: This was a retrospective cohort study about 8579 women who underwent the first IVF-ET from January, 2018 to August, 2021. Propensity Score Matching (PSM) was used to improve the comparability between two protocols.

Results: After PSM, significant higher live birth rates were found in the GnRH agonist long-acting protocol compared to GnRH antagonist protocol (44.04% vs. 38.32%) (p<0.001). Stratified analysis showed that for those with AMH levels between 3 ng/ml and 6 ng/ml, with BMI ≥ 24 kg/m2 and were aged ≥ 30 years old, and for those women with BMI < 24kg/m2 and were aged ≥30 years whose AMH levels were ≤ 3ng/ml, the GnRH agonist long-acting protocol was more likely to elicit live births [OR (95%CI), 2.13(1.19,3.80)], [OR (95%CI), 1.41(1.05,1.91)]. However, among women with BMI ≥ 24kg/m2 and were aged ≥30 years whose AMH levels were ≤ 3ng/ml, the GnRH agonist long-acting protocol had a lower possibility of eliciting live births [OR (95%CI), 0.54(0.32,0.90)]. Also, among women with AMH levels between 3 ng/ml and 6 ng/ml, with BMI ≥ 24 kg/m2 and with age < 30 years and for those with AMH levels between 3 ng/ml and 6 ng/ml, regardless of age, and with BMI<24kg/m2,, the possibility of live births was similar between the two protocols [OR (95%CI), 1.06(0.60,1.89)], [OR (95%CI), 1.38(0.97,1.97)], [OR (95%CI), 0.99(0.72,1.37)]. Among the women with AMH levels ≤ 3 ng/ml and with were aged < 30years, regardless of BMI, the possibility of live birth was similar between the two protocols [OR (95%CI), 1.02(0.68,1.54)], [OR (95%CI), 1.43(0.68,2.98)]. Moreover, among women with AMH levels ≥ 6ng/ml, the possibility of live birth was similar between the two protocols [OR (95%CI),1.42(0.75,2.69)], [OR (95%CI),1.02(0.19,5.35)], [OR (95%CI), 1.68(0.81,3.51)], [OR (95%CI), 0.51(0.10,2.55)].

Conclusions: The suitability of the GnRH agonist long-acting protocol or GnRH antagonist protocol to infertility patients is dependent on specific biological characteristics of the patients.

Keywords: GnRH agonist long-acting protocol; GnRH antagonist protocol; body mass index; live birth rate; ovarian reserve.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Flow chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bosch E, Ezcurra D. Individualised Controlled Ovarian Stimulation (Icos): Maximising Success Rates for Assisted Reproductive Technology Patients. Reprod Biol Endocrinol (2011) 9:82. doi: 10.1186/1477-7827-9-82 - DOI - PMC - PubMed
    1. Racca A, Drakopoulos P, Neves AR, Polyzos NP. Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. Drugs (2020) 80(10):973–94. doi: 10.1007/s40265-020-01324-w - DOI - PubMed
    1. Pacchiarotti A, Selman H, Valeri C, Napoletano S, Sbracia M, Antonini G, et al. . Ovarian Stimulation Protocol in Ivf: An Up-to-Date Review of the Literature. Curr Pharm Biotechnol (2016) 17(4):303–15. doi: 10.2174/1389201017666160118103147 - DOI - PubMed
    1. Geng Y, Xun Y, Hu S, Lai Q, Jin L. Gnrh Antagonist Versus Follicular-Phase Single-Dose Gnrh Agonist Protocol in Patients of Normal Ovarian Responses During Controlled Ovarian Stimulation. Gynecol Endocrinol (2019) 35(4):309–13. doi: 10.1080/09513590.2018.1528221 - DOI - PubMed
    1. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, et al. . Gnrh Agonist Versus Gnrh Antagonist in In Vitro Fertilization and Embryo Transfer (Ivf/Et). Reprod Biol Endocrinol (2012) 10:26. doi: 10.1186/1477-7827-10-26 - DOI - PMC - PubMed

Publication types

Substances